Top Players and Market Competition in the Non-Opioid Pain Patch Industry

The non-opioid pain patch market is positioned for significant expansion in the coming years, driven by evolving healthcare needs and innovative treatment options. With growing awareness around pain management alternatives and advances in drug delivery technology, this sector is on track to offer more effective and safer solutions for patients worldwide. Let's explore the market's growth outlook, key players, emerging trends, and the segmentation shaping its future.

Strong Growth Forecast for the Non-Opioid Pain Patch Market Size Through 2030
The non-opioid pain patch market is set to experience robust growth, projected to reach $4.69 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.5%. This upward trajectory is propelled by multiple factors, including the increasing occurrence of chronic pain, stronger regulatory support for non-opioid therapies, and technological progress in transdermal drug delivery systems. Moreover, heightened patient awareness regarding addiction-free pain relief options and the broadening use of these patches for neuropathic pain are critical contributors to market expansion. Key market trends expected to dominate include a growing preference for non-addictive pain treatments, wider adoption of topical and localized therapies, the rise of hybrid patches available both over-the-counter and by prescription, increased demand for chronic pain management solutions, and innovations that improve patch adhesion and prolong drug delivery duration.

Download a free sample of the non-opioid pain patch market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12230&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Non-Opioid Pain Patch Industry Forward
The non-opioid pain patch market features several prominent companies shaping its development. Among them are Hisamitsu Pharmaceutical Co. Inc., Teikoku Pharma USA Inc., Noven Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., Grünenthal GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Bayer AG, Iroko Pharmaceuticals LLC, Scilex Pharmaceuticals Inc., Zosano Pharma Corporation, Adynxx Inc., BioElectronics Corporation, NeuroMetrix Inc., Virpax Pharmaceuticals Inc., Novartis AG, DURECT Corporation, Eli Lilly and Company, and Endo Pharmaceuticals Inc.
Notably, in January 2024, Heron Therapeutics partnered with CrossLink Life Sciences to broaden the sales network for ZYNRELEF, a non-opioid pain relief solution designed for orthopedic surgeries. This collaboration aims to boost product adoption across the US, streamline patient access, and enhance postoperative pain management. CrossLink Life Sciences specializes as a private distributor focused on orthopedic, spine, and sports medicine devices in the US.

Emerging Innovations and Market Trends in Non-Opioid Pain Patches
Key market players are focusing on cutting-edge developments such as genetically validated target medicines, which utilize genetic insights to design drugs that directly interact with disease-related biological pathways. This method can improve therapeutic effectiveness while minimizing side effects.
For example, in February 2024, Latigo Biotherapeutics Inc., a biotech firm based in the US, introduced LTG-001, a selective inhibitor targeting the Nav1.8 sodium channel found primarily in peripheral nerve cells. By blocking this channel, LTG-001 aims to inhibit pain signals at their origin, offering promising pain relief without impacting the central nervous system. Phase 1 clinical trials showed that LTG-001 reaches its maximum concentration in about 1.5 hours, indicating a rapid onset of pain relief, which is crucial for managing both acute and chronic pain. Designed for oral use, LTG-001 provides a convenient alternative to injectable or topical treatments, potentially enhancing patient compliance and ease of use.

View the full non-opioid pain patch market report:
https://www.thebusinessresearchcompany.com/report/non-opioid-pain-patch-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Detailed Segmentation of the Global Non-Opioid Pain Patch Market
The report divides the non-opioid pain patch market based on several criteria:
1) By Patch Type:
- Lidocaine Patches
- Diclofenac Patches
- Capsaicin Patches
- ket*oprofen Patches
- Other Patches
2) By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
3) By Indication:
- Musculoskeletal Pain
- Neuropathic Pain

Further subcategories include:
- Lidocaine Patches: 5% Lidocaine Patch, Other Concentrations
- Diclofenac Patches: 1.3% Diclofenac Patch, Other Concentrations
- Capsaicin Patches: 8% Capsaicin Patch, Other Concentrations
- ket*oprofen Patches: 5% ket*oprofen Patch, Other Concentrations
- Other Patches: Combination Patches, Herbal Extract Patches, and other non-opioid varieties

This segmentation provides a comprehensive view of the diverse products and delivery channels that are expanding the reach and utility of non-opioid pain patches globally.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.